Dianthus Therapeutics Stock Price on November 27, 2024
| DNTH Stock | 23.83 0.03 0.13% |
Below is the normalized historical share price chart for Dianthus Therapeutics extending back to June 21, 2018. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Dianthus Therapeutics stands at 23.83, as last reported on the 29th of November, with the highest price reaching 23.99 and the lowest price hitting 23.07 during the day.
If you're considering investing in Dianthus Stock, it is important to understand the factors that can impact its price. Dianthus Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0416, which denotes the company had a -0.0416% return per unit of standard deviation over the last 3 months. Dianthus Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Dianthus Therapeutics' Coefficient Of Variation of (1,863), standard deviation of 3.83, and Mean Deviation of 2.81 to check the risk estimate we provide.
As of now, Dianthus Therapeutics' Total Stockholder Equity is increasing as compared to previous years. The Dianthus Therapeutics' current Stock Based Compensation is estimated to increase to about 3.8 M, while Common Stock Shares Outstanding is projected to decrease to under 3.2 M. . The current Price To Sales Ratio is estimated to decrease to 18.02. The current Price Earnings Ratio is estimated to decrease to -1.29. Dianthus Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 12th of September 2023 | 200 Day MA 26.1817 | 50 Day MA 26.8238 |
Dianthus |
Sharpe Ratio = -0.0416
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | DNTH |
Estimated Market Risk
| 3.88 actual daily | 34 66% of assets are more volatile |
Expected Return
| -0.16 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Dianthus Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Dianthus Therapeutics by adding Dianthus Therapeutics to a well-diversified portfolio.
Price Book 2.0873 | Enterprise Value Ebitda (7.35) | Price Sales 131.438 | Shares Float 13.6 M | Wall Street Target Price 51.8 |
Related Headline
Hasbro Headline on 27th of November 2024
Hasbro Inc Faces Class Action Lawsuit Over Alleged Securitie... by gurufocus.com
Hasbro Inc is facing a class action lawsuit filed by Bronstein, Gewirtz Grossman, LLC, a nationally recognized law firm. The lawsuit claims that Hasbro
Dianthus Therapeutics Valuation on November 27, 2024
It is possible to determine the worth of Dianthus Therapeutics on a given historical date. On November 27, 2024 Dianthus was worth 23.81 at the beginning of the trading date compared to the closed value of 23.83. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Dianthus Therapeutics stock. Still, in general, we apply an absolute valuation method to find Dianthus Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Dianthus Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Dianthus Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 23.24 | 24.24 | 22.89 | 23.86 | 170,510 | |
11/27/2024 | 23.81 | 23.99 | 23.07 | 23.83 | 186,580 |
| 23.81 | 23.99 | 23.07 | 23.83 | 0.00 |
| Backtest Dianthus Therapeutics | | | Dianthus Therapeutics History | | | Dianthus Therapeutics Valuation | Previous | Next |
Dianthus Therapeutics Trading Date Momentum on November 27, 2024
| On November 29 2024 Dianthus Therapeutics was traded for 23.83 at the closing time. The top price for the day was 23.99 and the lowest listed price was 23.07 . There was no trading activity during the period 0.0. Lack of trading volume on November 29, 2024 did not affect price variability. The overall trading delta against the current closing price is 0.08% . |
Dianthus Therapeutics Fundamentals Correlations and Trends
By evaluating Dianthus Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Dianthus Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Dianthus financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Dianthus Therapeutics Stock history
Dianthus Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Dianthus is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Dianthus Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Dianthus Therapeutics stock prices may prove useful in developing a viable investing in Dianthus Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 5.2 M | 3.2 M | |
| Net Loss | -25.6 M | -26.9 M |
Dianthus Therapeutics Quarterly Net Working Capital |
|
Dianthus Therapeutics Stock Technical Analysis
Dianthus Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Dianthus Therapeutics Period Price Range
Low | November 29, 2024
| High |
0.00 | 0.00 |
Dianthus Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Dianthus Therapeutics November 29, 2024 Market Strength
Market strength indicators help investors to evaluate how Dianthus Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Dianthus Therapeutics shares will generate the highest return on investment. By undertsting and applying Dianthus Therapeutics stock market strength indicators, traders can identify Dianthus Therapeutics entry and exit signals to maximize returns
Dianthus Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Dianthus Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Dianthus Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Dianthus to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.40) | |||
| Total Risk Alpha | (0.79) | |||
| Treynor Ratio | (0.14) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for Dianthus Stock analysis
When running Dianthus Therapeutics' price analysis, check to measure Dianthus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dianthus Therapeutics is operating at the current time. Most of Dianthus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dianthus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dianthus Therapeutics' price. Additionally, you may evaluate how the addition of Dianthus Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |